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Abstract
Purpose
After endoscopic resection (ER) of gastric tumors, eradication of Helicobacter pylori (H.
pylori) infection is advised to reduce metachronous recurrence. Optimal timing of such ther-
apy (yet to be established) was investigated herein, examining early active and late scarring
stages of post-ER iatrogenic ulcers.
Materials and Methods
Analysis included 514 patients who received proton-pump inhibitor (PPI)-based triple ther-
apy for H. pylori eradication after ER for gastric neoplasms between January 2008 and
June 2015. Clinicopathologic characteristics, particularly the timing of triple therapy, were
used to compare eradication rates, assigning patients to early- (2 weeks), intermediate-
(2–8 weeks), and late-phase (8 weeks) treatment groups.
Results
H. pylori eradication rates differed significantly by timing of triple therapy after ER (early,
90.0%; intermediate, 76.2%, late, 72.4%; p <.001). However, eradication success rates
were not significantly affected by age, smoking, alcohol consumption, preexisting comorbid-
ity, method of ER, size and location of iatrogenic ulcer, and duration of therapeutic regimen.
Early initiation of H. pylori eradication was also identified as a significant independent pre-
dictor of eradication success in multivariate analysis (Odds ratio = 3.67, 95% CI 2.18–6.16;
p <.001).
Conclusion
In patients undergoing ER of gastric tumors, early post-ER attempts at eradication of H.
pylori offer the best chance of eradication success.
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Introduction
Endoscopic resection (ER) is a widely accepted means of treating gastric adenomas and types
of early gastric cancer (EGC), generally through endoscopic submucosal dissection (ESD) or
endoscopic mucosal resection (EMR)[1,2]. Although the risk of developing a metachronous
gastric neoplasm elsewhere in the stomach is relatively high after ER[3], many studies have
shown that successful eradication ofHelicobacter pylori (H. pylori) may reduce this risk[4–9].
As with peptic ulcer disease (PUD), eradication ofH. pylori is thus an important therapeutic
indication in this setting, dictated by post-ER status[6,7,9–11].
Researchers are actively seeking ways to improve eradication rate of H. pylori, given the
gradually declining success rates due primarily to acquired antibiotic resistance[12–14]. Factors
impacting eradication ofH. pylori include smoking habits, alcohol consumption, age, body
mass index, underlying disease, CYP2C19 genotype, existing PUD, patient compliance, regi-
men duration, and of course antibiotic resistance[15–17]. Results of a recent study further
implicate the stage of PUD in eradication success[15]. However, few studies have addressed
factors influencing H. pylori eradication rates in the aftermath of ER, and none have focused
on the optimal timing of therapy to eradicateH. pylori post-ER.
Therefore, this study was conducted to evaluate whether differences in timing of eradication
therapy after ER of gastric tumors (early active vs late scarring stages of iatrogenic ulcers)
impacts success rates in eradicating H. pylori.
Methods
Patients
Overall, 1637 patients underwent ER of gastric neoplasms between January, 2008 and June,
2015 at Gangnam Severance Hospital. Among them, 514 post-ER recipients of proton-pump
inhibitor (PPI)-based triple therapy (i.e., PPI [standard dosing], amoxicillin 1.0 gm, clarithro-
mycin 500 mg; all taken bid) were selected for retrospective analysis. The patient selection and
grouping flow diagram is shown in Fig 1. Histories of gastric surgery or priorH. pylori eradica-
tion therapy and use of drugs affecting H. pylori positivity (PPI, histamine-2 receptor blocker,
or antibiotics) within the preceding 2 weeks were grounds for exclusion. The Institutional
Review Board (IRB) of Gangnam Severance Hospital approved this study. We received a con-
sent exemption from the IRB. Patients records and information was anonymized.
Fig 1. A flow chart of patient enrollment.
doi:10.1371/journal.pone.0162258.g001
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Study design
In addition to timing and duration of H. pylori eradication, specific clinicopathologic factors,
such as age, gender, smoking, alcohol consumption, preexisting comorbidity, method of ER
(e.g., EMR or ESD), size and location of iatrogenic ulcer, endoscopic finding of background
mucosa(e.g., mucosal atrophy or intestinal metaplasia) and histopathologic results, were col-
lected from medical records. We defined the patients who smoke presently as “smoker” and
the patient who drink more than 40g a day in men and more than 20g a day in women as as
“alcoholics”. And, “preexisting comorbidity” included following disorders; diabetes, hyperten-
sion, heart disease, liver disease, kidney disease, pulmonary disease, etc. Atrophy and intestinal
metaplasia were evaluated endoscopically at the time of ER. Atrophic gastric mucosa was
defined by whitish to yellowish color change, visible submucosal vessels and absence of rugae.
Intestinal metaplasia was characterized as metaplastic mucosa with fine or coarse plaques. The
size of ulcers created via ER were extrapolated from the excised specimens. In the post-ER
period, patients were grouped by timing (i.e., initiation) of therapy to eradicate H. pylori as fol-
lows: 1) early ( 2 weeks), 2) intermediate (2–8weeks) or 3) late ( 8weeks).
Diagnosis and treatment of H. pylori infection
H. pylori infection was determined by histologic sections (hematoxylin & eosin andWright-
Giemsa stains), by rapid urease test (Asan Helicobacter Test; Asan Pharmaceutical Co Ltd,
Seoul, Korea), and by serologic assay (IMMULITE 2000H. pylori IgG; Diagnostic Products
Corp [Siemens], Los Angeles, CA, USA). Infection was confirmed by either histologic means
or rapid urease test positivity, or by positive serologic assay, in the absence of medication to
eradicate H. pylori. Eradication ofH. pylori was achieved through PPI-based triple therapy,
consisting of PPI (standard dosing), amoxicillin (1.0 gm), and clarithromycin (500 mg), given
twice daily for 7–14 days after ER. Initiation of therapy varied, depending on physician or
patient preference, confirmation of infection (point in time), and follow-up scheduling. H.
pylori eradication was established by urea breath test or rapid urease test at least 4 weeks after
completion of triple therapy, and also at least 2 weeks after discontinuation of PPI or hista-
mine-2 receptor blocker due to the possibility of false negative result.
Statistical analysis
Between-group comparisons of clinicopathologic characteristics were conducted using chi-
square or Fisher’s exact test, applying Student t-test for non-categorical variables. Factors
impacting H. pylori eradication rates were subjected to logistic regression analysis. Statistical
significance was set at p<0.05. All computations relied on standard software (SPSS v18.0 for
Windows; SPSS Inc, Chicago, IL, USA).
Results
Demographic and clinicopathologic characteristics of subjects by
eradication status
In this cohort, the mean rate ofH. pylori eradication success was 81.9% (421/514). Clinicopath-
ologic characteristics of the study population are shown in Table 1, stratified by eradication
success (n = 421) and failure (n = 93). Age, smoking, alcohol consumption, underlying disease,
mean size of iatrogenic ulcer, location of iatrogenic ulcer, background mucosal status, and
tumor histology did not differ between groups. However, patient gender (male) and timing
(early) of attempts to eradicate H. pylori showed statistically significant associations withH.
pylori eradication rates (Table 1). Mean intervals from ER to initiation of triple therapy were
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65.3±122.8 days in the eradication success group and 120.9±175.7 days in the eradication fail-
ure group. In addition, demographic characteristics among early treatment (2weeks), inter-
mediate treatment (2–8weeks) and late treatement (8weeks) groups are shown in the table 2.
Moreover, we have further analyzed with a data that excluded the patients in whomH.pylori
infection was diagnosed by only serologic test (n = 146, 28.4%). This subgroup analysis also
showed that the early treatment group (2 weeks, n = 146) also achieved a significantly higher
eradication rate than did the intermediate (2–8 weeks, n = 27) or the late (8 weeks, n = 195)
treatment group (early, 91.8%; intermediate, 74.1%; late, 72.3%; p<.001) (Table 3).
Table 1. Univariate analysis affecting theHelicobacter pylori eradication rate.
Variables Success rate of eradication (%) Eradication success (N = 421) (n, %) Eradication failure (N = 93) (n, %) P
Age (years, mean ± SD) - 61.3 ± 10.7 59.9 ± 10.8 .230
Gender .003
Male 85.4 293 (69.6) 50 (53.8)
Female 74.9 128 (30.4) 43 (46.2)
Smoking 82.4 61 (14.5) 13 (17.6) .899
Drinking 82.3 188 (44.7) 40 (43.0) .773
Preexisting comorbidity .473
No 80.6 200 (47.5) 48 (51.6)
Yes 83.1 221 (52.5) 45 (48.4)
Method of ER .110
EMR 87.0 100 (23.8) 15 (16.1)
ESD 80.5 321 (76.2) 78 (83.9)
Iatrogenic ulcer size (mm) - 33.8 ± 15.5 34.8 ± 14.0 .565
Iatrogenic ulcer location .988
Upper 80.5 35 (8.3) 8 (8.6)
Middle 81.5 147 (34.9) 33 (35.5)
Lower 82.3 239 (56.8) 52 (55.9)
Endoscopic atrophy .706
No 79.5 97 (23.0) 25 (26.9)
Yes 82.0 324 (77.0) 68 (73.1)
Endoscopic IM .648
No 80.8 139 (33.0) 33 (35.5)
Yes 82.5 282 (67.0) 60 (64.5)
Tumor histology .136
Cancer 78.8 197 (46.8) 53 (57.0)
Dysplasia 83.7 169 (40.1) 33 (35.5)
Other 88.7 55 (13.1) 7 (7.5)
Duration of regimen .207
7-d triple therapy 81.4 316 (75.0) 75 (80.6)
10-d triple therapy 83.2 84 (20.0) 17 (18.3)
14-d triple therapy 95.5 21 (5.0) 1 (1.1)
Timing of HP eradication <.001
Early (2weeks) 90.0 242 (57.5) 27 (29.0)
Intermediate (2–8weeks) 76.2 32 (7.6) 10 (10.8)
Late (8weeks) 72.4 147 (34.9) 56 (60.2)
SD, standard deviation; ER, endoscopic resection; EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection; IM, intestinal metaplasia;
d, day; HP, Helicobacter pylori
doi:10.1371/journal.pone.0162258.t001
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H. pylori eradication rate relative to timing of triple therapy after ER
The early treatment group (2 weeks, n = 269) achieved a significantly higher eradication rate
than did the intermediate (2–8 weeks, n = 42) or the late (8 weeks, n = 203) treatment group
(early, 90.0%; intermediate, 76.2%; late, 72.4%; p<.001) (Fig 2).
Multivariate analysis of factors impacting H. pylori eradication rate
In multivariate analysis, assessing gender, duration of treatment(documented as significant fac-
tor in previous studies,[18] although they were not significant in our results), and timing of H.
pylori eradication after ER, early initiation of H. pylori eradication and male gender were iden-
tified as significant independent predictors of eradication success (Odds ratio [OR] = 3.67, 95%
CI 2.18–6.16; p<.001) (Table 4).
Discussion
To prevent metachronous lesions after ER of gastric tumors, especially in instances of EGC,
eradication ofH. pylori is an important therapeutic adjunct[4–9] that is incorporated in most
treatment guidelines[19]. However, the optimal timing of eradicative therapy has yet to be
addressed in this setting. Outcomes of the present study are the first to show that early initia-
tion of such treatment after ER, in the active reparative phase of iatrogenic ulcers, is indepen-
dently predictive of H. pylori eradication success (OR = 3.67, 95% CI 2.18–6.16; p<.001).
Success rates in eradicating H. pylori have gradually declined in many countries due to
acquired microbial resistance to antibiotics. Recently, Shin et al. reported thatH. pylori eradica-
tion rates with clarithromycin-containing triple therapy in Korea showed a decreasing trend
over the past 10 years. The eradication rates of triple therapy ranged 84.9–87.5% from 2001 to
2007, and 80.0–81.4% from 2008 to 2010[20]. Although current guidelines[19,21,22] still rec-
ommend triple therapy (clarithromycin, amoxicillin, and a PPI) for 7–14 days as the standard
eradication regimen, new strategies are urgently needed. In this study, the overall eradication
rate of triple therapy was somewhat high because early eradication group achieved a signifi-
cantly high eradication rate (overall, 81.9%; early, 90.0%; intermediate, 76.2%; late, 72.4%).
Many studies have found that post-ER iatrogenic ulcers tend to heal within 8 weeks[23–25],
supporting Sakita’s three-stage reparative classification as follows [26]: 1) active-to-healing
Table 2. Comparisons of the demographic findings among early treatment, intermediate treatment, and late treatment groups.
Variables Early treatment group (N = 269) Intermediate treatment group (N = 42) Late treatment group (N = 203) P
Age (years, mean ± SD) 60.9 ± 11.3 60.3 ± 10.9 61.5 ± 9.8 .723
Gender .171
Male 170 (63.2) 28 (66.7) 145 (71.4)
Female 99 (36.8) 14 (33.3) 58 (28.6)
Smoking 30 (11.2) 7 (16.7) 37 (18.2) .087
Duration of regimen .015
7-d triple therapy 205 (76.2) 26 (61.9) 160 (78.8)
10-d triple therapy 47 (17.5) 14 (33.3) 40 (19.7)
14-d triple therapy 17 (6.3) 2 (4.8) 3 (1.5)
Success of HP eradication <.001
Yes 242 (90.0) 32 (76.2) 147 (72.4)
No 27 (10.0) 10 (23.8) 56 (27.6)
SD, standard deviation; d, day; HP, Helicobacter pylori
doi:10.1371/journal.pone.0162258.t002
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stage ( 2 weeks), 2) healing-to-scarring stage (2–8 weeks), and 3) scarring stage ( 8weeks).
Our discovery that early initiation of triple therapy after ER is independently predictive of
eradication success may then be linked with ongoing active gastric repair at sites of ER. Previ-
ous investigations have also reported thatH. pylori eradication rates are higher in patients with
PUD than in patients with non-ulcerative dyspepsia[16,27,28]. Moreover, Seo et al reported
that active ulcers were likewise found to be independent predictors of successful eradication
and concluded that earlyH.pylori eradication should be considered in patients with peptic
Table 3. Univariate analysis affecting theHelicobacter pylori eradication rate in subgroup in which diagnosis of infection wasmade by histology
or rapid urease test.
Variables Success rate of eradication (%) Eradication success (N = 295) (n, %) Eradication failure (N = 73) (n, %) P
Age (years, mean ± SD) - 60.9 ± 10.9 61.3 ± 10.5 .782
Gender .061
Male 83.0 200 (67.8) 41 (56.2)
Female 74.8 95 (32.2) 32 (43.8)
Smoking 80.7 42 (14.2) 10 (13.7) .987
Drinking 79.5 128 (43.4) 33 (45.2) .960
Preexisting comorbidity .776
No 79.5 140 (47.5) 36 (49.3)
Yes 80.7 155 (52.5) 37 (50.7)
Method of ER .363
EMR 83.8 67 (22.7) 13 (17.8)
ESD 79.2 228 (77.3) 60 (82.2)
Iatrogenic ulcer size (mm) - 33.2 ± 14.7 33.9 ± 14.0 .709
Iatrogenic ulcer location .782
Upper 75.9 22 (7.5) 7 (9.6)
Middle 79.5 97 (32.9) 25 (34.2)
Lower 81.1 176 (59.6) 41 (56.2)
Endoscopic atrophy .965
No 81.2 69 (23.4) 16 (21.9)
Yes 79.9 226 (76.6) 57 (78.1)
Endoscopic IM .581
No 78.6 99 (33.6) 27 (37.0)
Yes 81.0 196 (66.4) 46 (63.0)
Tumor histology .056
Cancer 74.9 128 (43.4) 43 (58.9)
Dysplasia 84.2 123 (41.7) 23 (31.5)
Other 86.3 44 (14.9) 7 (9.6)
Duration of regimen .055
7-d triple therapy 78.0 216 (73.2) 61 (83.6)
10-d triple therapy 83.6 61 (20.7) 12 (16.4)
14-d triple therapy 100.0 18 (6.1) 0 (0.0)
Timing of HP eradication <.001
Early (2weeks) 91.8 134 (45.4) 12 (16.4)
Intermediate (2–8weeks) 74.1 20 (6.8) 7 (7.6)
Late (8weeks) 72.3 141 (47.8) 54 (74.0)
SD, standard deviation; ER, endoscopic resection; EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection; IM, intestinal metaplasia;
d, day; HP, Helicobacter pylori
doi:10.1371/journal.pone.0162258.t003
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ulcer bleeding for higher eradication rate[15]. Unfortunately, the mechanisms responsible for
differing eradication rates as ulcers heal remain unclear.
The disparate levels of inflammatory immune reactivity inherent in active and scarred gas-
tric ulcers or defects may offer one explanation. In this regard, a significantly higher eradication
rate has been observed by Malfertheiner et al, correlating with intense (vs mild) neutrophilic
infiltration of gastric antrum[29]. It may well be that therapeutic efficacy is improved in the
absence of gastric mucus and epithelial layers, thus encouraging penetration of charged antibi-
otics from stomach lumen and facilitating systemic drug delivery through altered epithelial and
vascular permeability[27]. Hence, inflammatory reactions quite conceivably may render H.
pylori infections more susceptible to antibiotic therapy, conferring higher eradication rates in
the context of active repair.
Fig 2. H. pylori eradication rate according to timing of therapeutic regimen after ER: a significantly
higher eradication rate was achieved with treatment initiated early, compared with intermediate- or
late-phase initiation (early, 90.0%; intermediate, 76.2%; late, 72.4%; p <.001).
doi:10.1371/journal.pone.0162258.g002
Table 4. Multivariate analysis affecting theHelicobacter pylori eradication rate.
Factors Odds ratio (95% CI) P
Gender Female 1
Male 2.37 (1.46–3.84) <.001
Duration of regimen 7-d triple therapy 1
10-d triple therapy 4.19 (0.53–32.77) .171
14-d triple therapy 3.22 (0.39–26.46) .277
Timing to HP eradication Late (8weeks) 1
Intermediate (2–8weeks) 3.14 (1.36–7.24) .007
Early (2weeks) 3.67 (2.18–6.16) <.001
CI, Conﬁdence interval; d, day; HP, Helicobacter pylori
doi:10.1371/journal.pone.0162258.t004
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Our analysis also revealed a significant association between male gender and H. pylori eradi-
cation success, although this finding appears controversial. Moayyedi et al have reported simi-
lar results, citing gender-related differences in gastric physiology[30], and recently, Lee et al
provided further confirmation[31]. However, no such relationship was evident in another
study[32], casting doubt on the impact of gender in eradication of H. pylori.
There was no guideline regarding the optimal timing ofH. pylori eradication in post-ER set-
ting. As noted by Cheon et al., early therapy to eradicate H. pylorimay additionally serve to
speed the healing of post-ER iatrogenic ulcers[33]. However, because patients may experience
nausea, dyspepsia or abdominal pain immediately after ER[34], some physicians prefer to
delayH. pylori eradication for this reason. We nevertheless maintain that early initiation of
therapy after ER is a sound rationale, capable of enhancing eradication success. However, early
eradication therapy should be reconsidered in patients with acute symptoms after ER (e.g.,
nausea, dyspepsia or abdominal pain) for it may affect not only the patient’s quality of life but
also completion rate of eradication therapy.
Our study has several acknowledged limitations. First, the analysis was retrospective and
non-randomized, causing unavoidable potential for selection bias. And for the same reason, we
could not evaluate the side effects and completion rates of eradication therapy in each groups.
In addition, the duration of regimen showed differences among three groups (early treatment,
intermediate treatment, late treatment groups). Although there was no significant difference in
eradication rate of H.pylori according to the duration of regimen (p = 0.207), it is also a limita-
tion of this study. Finally, assays of bacterial antibiotic resistance were not feasible. Therefore,
further randomized prospective study is needed to validate our result. Nevertheless, our result
yields important clues in clinical practice as to whenH. pylori eradication should be initiated in
patients who underwent ER for gastric neoplasm.
In conclusion, early treatment to eradicate H. pylori, initiated2 weeks after ER of gastric
tumors, emerged in this study as an independent predictor of eradication success and is thus
encouraged as an important therapeutic adjunct, although further prospective study is needed
to validate our result.
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